Related Experiment Video

Updated: Feb 7, 2026

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.7K

Pathogenic Factors in Postinfectious Irritable Bowel Syndrome - An Update

Teodora Iacob, Doina F Ţăţulescu, Cristina Cijevschi Prelipcean

    Revista Medico-Chirurgicala a Societatii De Medici Si Naturalisti Din Iasi
    |July 26, 2018
    PubMed

    Insights

    Up to 30% of patients experience prolonged gastrointestinal issues post-gastroenteritis. New Rome IV criteria recognize postinfectious irritable bowel syndrome (PI-IBS) as a distinct entity linked to mucosal inflammation.

    Area of Science:

    • Gastroenterology
    • Microbiology
    • Immunology

    Background:

    • Acute infectious gastroenteritis can lead to persistent gastrointestinal symptoms in a significant patient subset.
    • A portion of these patients meet diagnostic criteria for postinfectious irritable bowel syndrome (PI-IBS).
    • Historically, PI-IBS diagnosis relied on the Rome III criteria.

    Purpose of the Study:

    • To outline the diagnostic evolution of PI-IBS.
    • To highlight the impact of the Rome IV criteria on PI-IBS classification.
    • To underscore the proposed underlying pathophysiology of PI-IBS.

    Main Methods:

    • Review of diagnostic criteria evolution for PI-IBS.
    • Analysis of changes introduced by Rome IV criteria.
    • Examination of the role of chronic mucosal inflammation in PI-IBS pathogenesis.

    Main Results:

    • The Rome IV criteria represent an update to the diagnostic standards for PI-IBS.
    • PI-IBS is now recognized as a specific entity within the Rome IV framework.
    • Chronic mucosal inflammation, triggered by enteric infection, is implicated in the persistent symptoms of PI-IBS.

    Conclusions:

    • The Rome IV criteria offer a refined approach to diagnosing PI-IBS.
    • Understanding the role of mucosal inflammation is key to comprehending PI-IBS.
    • This classification acknowledges the specific pathophysiology of PI-IBS following infection.

    More Related Videos

    Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

    Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

    Published on: September 20, 2024

    901
    Eye Irritation Test EIT for Hazard Identification of Eye Irritating Chemicals using Reconstructed Human Cornea-like Epithelial RhCE Tissue Model10:13

    Eye Irritation Test EIT for Hazard Identification of Eye Irritating Chemicals using Reconstructed Human Cornea-like Epithelial RhCE Tissue Model

    Published on: August 23, 2015

    40.2K

    Related Concept Videos

    Irritable Bowel Syndrome I: Introduction01:17

    Irritable Bowel Syndrome I: Introduction

    Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
    IBS is a chronic condition that can persist over a long period or recur frequently.
    The pathogenesis of IBS involves a complex interplay of the following factors:
    Altered...
    1.0K
    Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

    Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

    Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
    Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
    821
    Irritable Bowel Syndrome III: Medical and Nursing Management01:30

    Irritable Bowel Syndrome III: Medical and Nursing Management

    Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
    793
    Chronic Bowel Disorders: Introduction01:17

    Chronic Bowel Disorders: Introduction

    Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
    Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
    808
    Transcription Factors02:16

    Transcription Factors

    Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
    82.8K
    Inflammatory Bowel Disease I: Ulcerative Colitis01:27

    Inflammatory Bowel Disease I: Ulcerative Colitis

    Introduction
    Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
    Risk Factors
    The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
    1.0K